HARRISON, N.Y., Oct. 29, 2021 /PRNewswire/ – Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today that it will present multiple posters on its lead program, ST101, at the 28th Prostate Cancer Foundation (PCF) Annual Scientific Retreat, being held virtually October 28- 29th, 2021 and November 4-5, 2021, and the 18th International Congress of the Society for Melanoma Research, being held virtually October 28-31, 2021.
Presentation details for the posters are as follows:
Society for Melanoma Research
- Presentation Title: Efficacy, safety, PK and PD data from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients with advanced and metastatic solid tumors
- Date/Time: October 28, 2021 from 3:00 PM-4:30 PM ET
- Presentation Title: C/EBPβ antagonist peptide, ST101, as a novel therapeutic for melanoma
- Date/Time: October 28, 2021 from 3:00 PM-4:30 PM …